Celebrating his first year as CEO of Citryll, Eduardo offers a unique perspective on his journey so far. In this exclusive interview, he reflects on the past year's challenges, achievements, and strategic initiatives that have driven the company forward.

The Phase 1 first-in-human trial is assessing the safety and tolerability of CIT-013. Part D of the Phase 1 trial is investigating the safety and tolerability of repeat dosing in 9 patient volunteers with rheumatoid arthritis (RA) and 3 healthy volunteers.